Evidence map›Paper›PMID 40594400›Full record

ArticleScientific reports2025

Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer.

Alice Filipe, Sayeh Saravi, Denis Mustafov, Suzana Panfilov, Simran Banger, Seyedehnajmeh Mousavikivaj, Maria Braoudaki, Senthilkumar Kailasam, Yasser Riazalhosseini, Michelle A Sahai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alice FilipeDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Sayeh SaraviDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Denis MustafovDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Suzana PanfilovDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Simran BangerDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Seyedehnajmeh MousavikivajDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Maria BraoudakiSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9JA, UK.
Senthilkumar KailasamVictor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, QC, H3A 0G4, Canada.
Yasser RiazalhosseiniVictor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montreal, QC, H3A 0G4, Canada.
Michelle A SahaiDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Fotios DrenosDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Cristina SisuDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK.
Emmanouil KarterisDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, Uxbridge, UB8 3PH, UK. emmanouil.karteris@brunel.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of in silico tools, clinical samples and in vitro models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall-and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects of CIP2A inhibition in an in vitro BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role of CIP2A in OvCa and the potential of drug repurposing for therapeutic interventions.

Indexed as

AutoantigensIntracellular Signaling Peptides and ProteinsMembrane ProteinsOvarian NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMicroRNAsMutationAutoantigensCIP2A protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsMicroRNAs

Identifiers

PMID40594400
PMCPMC12214521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.